NEW YORK -- Pfizer says the Food and Drug Administration approved its rheumatoid arthritis pill Xeljanz (ZEL'jans), seen as potential big seller for the world's largest pharmaceutical company.Pfizer Inc. says the FDA approved Xeljanz as a treatment for moderate to severe rheumatoid arthritis in patients who can't take methotrexate or haven't been helped by it.